Liposomal amphotericin B dosing in ECMO patients
Part of Infections clinical trials.
This trial studies how the body processes the antifungal drug liposomal amphotericin B (L-AmB) in patients on ECMO (a heart-lung machine). The goal is to find the right dose for treating invasive fungal infections in ICU patients who need ECMO support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in the intensive care unit (ICU) with a confirmed or suspected invasive fungal infection.
- You are currently on ECMO (extracorporeal membrane oxygenation) life support.
- You are 18 years or older.
- You must not be pregnant.
- You must have survived longer than 24 hours at the time of enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how liposomal amphotericin B (a drug used to treat serious fungal infections) moves through the body in people who are critically ill versus those who are not. It may help doctors choose safer and more accurate dosing for patients with blood-related illnesses.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This study measures how the body processes a common antifungal medicine (liposomal amphotericin B) in patients who have a serious fungal infection and are also undergoing plasma exchange—a treatment that filters and cleans the blood. Understanding these drug levels may help doctors give better doses.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
Hear when a new Invasive Fungal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.